Anti-PD-1

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer
Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital B Shnerb, Sooraj Mathukkada, Jebrane Bouaoud, Lucas Michon, Ofra Novoplansky, Mai Badarni, Limor Cohen, Ksenia M Yegodayev, Sapir Tzadok, Barak Rotblat, Libor Brezina, Andreas Mock, Andy Karabajakian, Jérôme Fayette, Idan Cohen, Tomer Cooks, Irit Allon, Orr Dimitstein, Benzion Joshua, Dexin Kong, Elena Voronov, Maurizio Scaltriti, Yaron Carmi, Cristina Conde-Lopez, Jochen Hess, Ina Kurth, Luc G T Morris, Pierre Saintigny, Moshe Elkabets

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003917; DOI: 10.1136/jitc-2021-003917
Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition
Girish S. Naik, Sushrut S. Waikar, Alistair E. W. Johnson, Elizabeth I. Buchbinder, Rizwan Haq, F. Stephen Hodi, Jonathan D. Schoenfeld, Patrick A. Ott

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 89; DOI: 10.1186/s40425-019-0512-5
Exploring the emerging role of the microbiome in cancer immunotherapy
Jessica Fessler, Vyara Matson, Thomas F. Gajewski

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 108; DOI: 10.1186/s40425-019-0574-4
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials
Jia-Wei Lv, Jun-Yan Li, Lin-Na Luo, Zi-Xian Wang, Yu-Pei Chen

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 159; DOI: 10.1186/s40425-019-0636-7
Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment
Daan P. Hurkmans, Jeroen G. H. P. Verhoeven, Kitty de Leur, Karin Boer, Arjen Joosse, Carla C. Baan, Jan H. von der Thüsen, Ron H. N. van Schaik, Ron H. J. Mathijssen, Astrid A. M. van der Veldt, Dennis A. Hesselink

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 182; DOI: 10.1186/s40425-019-0653-6
Anti-TNF, a magic bullet in cancer immunotherapy?
Anne Montfort, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer, Bruno Ségui

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 303; DOI: 10.1186/s40425-019-0802-y
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
Douglas D. Fang, Qiuqiong Tang, Yanhui Kong, Qixin Wang, Jiaxing Gu, Xu Fang, Peng Zou, Tao Rong, Jingwen Wang, Dajun Yang, Yifan Zhai

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 327; DOI: 10.1186/s40425-019-0750-6
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
Paolo A. Ascierto, Mariaelena Capone, Antonio M. Grimaldi, Domenico Mallardo, Ester Simeone, Gabriele Madonna, Heinrich Roder, Krista Meyer, Senait Asmellash, Carlos Oliveira, Joanna Roder, Julia Grigorieva

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 91; DOI: 10.1186/s40425-019-0569-1
The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018
Paolo A. Ascierto, Lisa H. Butterfield, Sandra Demaria, Robert L. Ferris, Gordon J. Freeman, Roger S. Lo, Alberto Mantovani, Paul Nathan, Omid Hamid, Katerina Politi, Igor Puzanov

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 221; DOI: 10.1186/s40425-019-0683-0
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Bridgette A. Kanz, Megan H. Pollack, Romany Johnpulle, Igor Puzanov, Leora Horn, Alicia Morgans, Jeffrey A. Sosman, Suthee Rapisuwon, R. Martin Conry, Zeynep Eroglu, Douglas B. Johnson

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 60; DOI: 10.1186/s40425-016-0166-5

Main menu

Anti-PD-1

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Anti-PD-1

Pages